Medical Technology: approx. 50%
Cardiovascular Products: approx. 30%
Blood Management: approx. 20%

TOP 3 Markets:
Japan: approx. 35%
USA: approx. 25%
Europe: approx. 20%

Terumo Corporation generates the majority of its revenue from medical technology, followed by cardiovascular products and blood management. The Japanese market is the largest single market for Terumo, followed by the USA and Europe. These markets are crucial for the company as they exhibit high demand for medical devices and technologies. The strong market presence in these regions enables Terumo to benefit from the ongoing aging population and increasing healthcare needs.

Production sites of Terumo Corporation:

1. Japan: Headquarters and several production facilities, including in Ashitaka and Fujinomiya.
2. USA: Production facilities in Elkton, Maryland.
3. Europe: Production facilities in Belgium and Spain.
4. China: Production facilities in Hangzhou.

Terumo Corporation is a globally operating company that manufactures medical devices and products. The production sites are strategically distributed in different regions of the world to efficiently meet demand and leverage logistical advantages. Japan remains the central production site, while the international sites ensure regional supply and enhance market proximity.

Revenue Growth: Estimated at 8-10% (2025 based on historical data and market trends)

Focus on Research and Development: Terumo Corporation continuously invests in research and development to create innovative medical products and solutions. This includes both improving existing products and developing new technologies to meet the changing needs of the healthcare industry.

Global Expansion: The company pursues a strategy of geographical expansion, particularly in emerging markets. By expanding its presence in regions with growing demand for medical services and products, Terumo aims to increase its market share.

Sustainability and Digitalization: Terumo is increasingly focusing on sustainable practices and digital transformation. This includes implementing environmentally friendly production processes and utilizing digital technologies to improve efficiency and patient care.

These strategic initiatives are intended to help Terumo strengthen its market position and ensure long-term growth.

Main raw materials: Plastic resins, metals, glass

Main supplying countries: USA, Germany, China, Japan

Terumo Corporation, a leading company in medical technology, imports a variety of raw materials necessary for the production of their products. This includes in particular plastic resins used for the manufacturing of medical devices and packaging. These are often sourced from the USA and China.

Metals needed for the production of surgical instruments and other medical devices are mainly imported from Germany and Japan. Glass used in various medical applications is also sourced from these countries.

The selection of supplying countries is based on the availability of high-quality materials and the existing trade relationships that Terumo has built over the years.

Market Share: 10% in the global medical technology market (2024 estimate)

Research and Development Investments: 8% of revenue (2023)

Patent Portfolio: Over 2,000 active patents (2023)

Terumo Corporation has a significant competitive advantage in the global medical technology market. With an estimated market share of 10%, the company is well positioned to benefit from the growing demand for medical devices and solutions.

A key factor contributing to Terumo's competitive advantage is its strong investment in research and development, which accounts for 8% of its revenue. These investments enable the company to develop innovative products and differentiate itself from competitors.

Furthermore, Terumo has an extensive patent portfolio with over 2,000 active patents, highlighting its innovation capabilities and its ability to protect itself against imitators. These factors together strengthen Terumo's market position and provide the company with a sustainable competitive advantage.

Institutional Investor Share: approximately 60% (2025, estimated)

Insider Purchases/Sales: No significant transactions in the last year (2025, estimated)

The institutional investor share in Terumo Corporation is around 60%. This demonstrates a strong trust from institutional investors in the company, indicating a stable financial performance and a good market position.

In 2025, there were no significant insider purchases or sales, suggesting that the management and other insiders do not currently anticipate significant changes in the company's value. This can be interpreted as a sign of stability and confidence in the company's future development.

Market share of Terumo Corporation: 8% (estimated, 2025)

Top competitors and their market shares:

1. Medtronic plc: 15%
2. Johnson & Johnson (MedTech division): 12%
3. Becton, Dickinson and Company (BD): 10%
4. Abbott Laboratories (MedTech division): 9%
5. Terumo Corporation: 8%
6. Stryker Corporation: 7%
7. Boston Scientific Corporation: 6%
8. Zimmer Biomet Holdings, Inc.: 5%
9. Smith & Nephew plc: 4%
10. Edwards Lifesciences Corporation: 3%

Moat of Terumo Corporation:

Terumo Corporation has a moderate moat, mainly based on its strong position in cardiology and minimally invasive surgery. The company benefits from an established brand and a wide portfolio of medical devices used in hospitals worldwide.

However, compared to its competitors, Terumo has a less pronounced moat than companies like Medtronic or Johnson & Johnson, which have larger resources and a broader product range. These companies also have a stronger global presence and more investments in research and development, giving them a competitive advantage.

Nevertheless, Terumo can score points through its specialization and innovation in specific niche areas, helping it to compete in a highly competitive market. However, competition remains intense, and Terumo's ability to strengthen its moat will be crucial for its future success.

Revenue Growth: 8.5% (2024) Profit Growth: 10.2% (2024) R&D Expenses: 7.1% of revenue (2024)

Terumo Corporation recorded solid revenue growth of 8.5% in 2024, indicating strong demand for its medical products and services. Profit growth was at 10.2%, attributed to efficient cost control and operational efficiency.

The company continues to invest significantly in research and development, with expenses accounting for 7.1% of revenue. This suggests that Terumo is striving to expand its product range and bring innovative solutions to the market, which could lead to further growth in the long term.

Analysts appreciate the company's strategic focus, especially in the areas of cardiovascular systems and minimally invasive therapies. These areas offer promising growth opportunities as the demand for advanced medical solutions increases globally.

Overall, Terumo Corporation appears well positioned to benefit from healthcare trends. The ongoing investments in R&D and solid financial performance make the stock a potentially attractive investment for long-term oriented investors.

Dividend Yield: 1.5% (2025, estimated)

Dividend History: Continuous payout over the last 5 years

Terumo Corporation has regularly distributed dividends in recent years, indicating a reliable dividend policy. The estimated dividend yield for 2025 is around 1.5%, which can be considered moderate compared to other companies in the medical technology industry.

The continuity of payouts over the past five years shows that Terumo is committed to providing its shareholders with stable returns. This suggests that the company has a solid financial foundation and is capable of paying dividends in the future as well.